25th ANNIVERSARY OF CLONING BY SOMATIC-CELL NUCLEAR TRANSFER

Scientific and technological approaches to improve SCNT efficiency in farm animals and pets

Pasqualino Loi¹, Luca Palazzese², Pier Augusto Scapolo¹, Josef Fulka Jr³, Helena Fulka⁴ and Marta Czernik^{1,2}

¹Laboratory of Embryology, Faculty of Veterinary Medicine, University of Teramo, Teramo, Abruzzo, Italy, ²Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Warsaw, Jastrzebiec, Poland,

³Department of Biology of Reproduction, Institute of Animal Science, Prague, Pratelstvi, Czech Republic and

⁴Department of Cell Nucleus Plasticity, Institute of Experimental Medicine of the Czech Academy of Sciences, Praha, Czech Republic

Correspondence should be addressed to P Loi; Email: ploi@unite.it

This paper forms part of an anniversary issue on the 25th Anniversary of cloning by somatic cell nuclear transfer. The Guest Editor for this section was Professor Kevin Sinclair, University of Nottingham, UK

Abstract

The birth of Dolly through somatic cell nuclear transfer (SCNT) was a major scientific breakthrough of the last century. Yet, while significant progress has been achieved across the techniques required to reconstruct and *in vitro* culture nuclear transfer embryos, SCNT outcomes in terms of offspring production rates are still limited. Here, we provide a snapshot of the practical application of SCNT in farm animals and pets. Moreover, we suggest a path to improve SCNT through alternative strategies inspired by the physiological reprogramming in male and female gametes in preparation for the totipotency required after fertilization. Almost all papers on SCNT focused on nuclear reprogramming in the somatic cells *after* nuclear transfer. We believe that this is misleading, and even if it works sometimes, it does so in an uncontrolled way. Physiologically, the oocyte cytoplasm deploys nuclear reprogramming machinery specifically designed to address the male chromosome, the maternal alleles are prepared for totipotency earlier, during oocyte nuclear maturation. Significant advances have been made in remodeling somatic nuclei *in vitro* through the expression of protamines, thanks to a plethora of data available on spermatozoa epigenetic modifications. Missing are the data on large-scale nuclear reprogramming of the oocyte chromosomes. The main message our article conveys is that the next generation nuclear reprogramming strategies should be guided by insights from in-depth studies on epigenetic modifications in the gametes in preparation for fertilization.

Reproduction (2021) **162** F33–F43

Introduction

The writing of this manuscript for the *Reproduction* special issue revived the memories of laboratories brimming with atmosphere, just a handful at the time, working on nuclear transfer. The production of the first lambs cloned by electrofusion of blastomeres from early embryos onto enucleated oocytes (Willadsen 1986) started a race between groups to optimize nuclear transfer, then a black box from the scientific point of view. On the one hand, considerable efforts were spent trying to synchronize the cell cycle between the receiving enucleated oocyte (cytoplasm) and the donor nuclei (karyoplast) (Smith *et al.* 1988, Campbell *et al.* 1994, 1996a); on the other hand, attempts were made to use more advanced embryonic cells to increase the

number of obtainable clones (First 1990, Sims & First 1994). The core of the game at the time was played in the United Kingdom. The Bovine Embryo Multiplication Agreement (BEMA) represented a brainstorming and empirical ring in which most of the game was set. Keith Campbell's intuition was based on the initially assumed importance of inducing a G0-stage in the donor nuclei to achieve better reprogramming. However, this was later reduced to a cell-cycle synchronization method and culminated in cloned lambs from cultured embryonic cells (Campbell *et al.* 1996b). This was shortly followed by the production of Dolly, the sheep whose 25th anniversary is celebrated in this special issue (Wilmut *et al.* 1997).

The formidable energy deployed at that time jumped the gun: contrary to data reported in amphibians, where

terminally differentiated cells from adult individuals did not develop past feeding tadpoles (Gurdon *et al.* 1975), the prospects of multiplying adult animals were made real. SCNT is a multistep process that relies on several factors such as oocyte quality, activation procedures, donor nuclei source and their cell-cycle stage, culture system, and the global efficiency derived from all these. A review covering all these aspects would be dispersive and unmanageable. However, the reader is referred to several authoritative reviews written on different aspects of SCNT (Narbonne *et al.* 2012, Ogura *et al.* 2013, Simmet *et al.* 2020, Wang *et al.* 2020). Here, we would like to focus on nuclear reprogramming and particularly on the strategies attempted thus far to induce global genome modifications in somatic cells. The general goal of these attempts was to induce an epigenetic asset amenable to establish a totipotent state upon nuclear transfer. We apologize for not including all valuable works published to date on other important aspects of SCNT.

State-of-the-art

Many are the published reports on SCNT. A PubMed survey launched at the time of this manuscript preparation counted 3152 publications since the original Dolly paper (Fig. 1). An in-depth data analysis revealed that while several significant technical improvements have been achieved in the reconstruction, activation, and *in vitro* culture of SCNT embryos, no major advancements in nuclear transfer efficiency in terms of offspring development have been made. However, a distinction must be made between mice and other species. The laboratory mouse (*Mus musculus domesticus*), thanks to its genetically defined strains, availability of a large volume of genetic information, and relatively easy generation of gene-modified animals are an unmatched model for SCNT research, as a companion paper published in this issue will show.

Figure 1 Number of publications since the production of Dolly (March 1997–December 2020, Pubmed survey December 2020).

Here we will briefly quote the main innovation reported in mice, as presented by Ogura (2020):

- (i) Exposure of cloned embryos to histone deacetylase inhibitors (Kishigami *et al.* 2006).
- (ii) Removal of Reprogramming Resistant Regions (RRRs), represented by genomic domains enriched in H3K9me3, using the ectopic expression of H3K9me3 demethylase Kdm4d (Matoba *et al.* 2014).
- (iii) Correction of the Xist expression pattern in SCNT-derived embryos by Xist gene knockout or knockdown (Matoba *et al.* 2011).

Consistent data on large animal SCNT are available only for donor cell treatment and reconstructed embryos with diverse histone deacetylase inhibitors, Trichostatin A (TSA) being the most common. TSA treatment was pioneered by Kishigami and Wakayama, resulting in a dramatic increase in live offspring (Kishigami *et al.* 2006). The leap in offspring production clearly resulted from an improved nuclear reprogramming of the somatic cells, although the exact mechanisms through which TSA works remain elusive. TSA ‘opens’ the chromatin structure in reconstructed embryos, making it more available to transcription factors during early nuclear remodeling, and facilitates the remodeling of constitutive heterochromatin. Indeed, the early embryo genome, also in cloned embryos, undergoes the most dynamic transcription phase a genome ever experiences. Chromatin de-condensation after TSA treatment and histone acetylation results in easier access of many, still unknown, remodeling factors from the ooplasm (Maalouf *et al.* 2009). Overall, it could be stated that the effects of TSA on nuclear reprogramming mechanisms in farm animal SCNT remain controversial and need further investigation, especially on the development to term (Sangalli *et al.* 2012, Sawai *et al.* 2012, Hosseini *et al.* 2016). A study in pigs claimed to have enhanced offspring production following TSA treatment, but an in-depth analysis of the data revealed that the development to term rates of TSA treated and control SCNT embryos were 0.7 and 0.4%, respectively (Huan *et al.* 2015). Less informative are the data on TSA treatment during SCNT in pets, given that almost all the reports concerned interspecific SCNT – iSCNT (Wittayarat *et al.* 2013).

If TSA does not endow significant advantages on large animal SCNT outcomes, the picture does not change much following the application of maternal Xist knockout in donor cells and/or Kdm4d mRNA injection into reconstructed embryos, mentioned earlier. In a recent cattle SCNT study, inhibition of the epigenetic writer EHMT1/2 catalytic activity markedly reduced H3K9me2 and H3K9me3 levels in cloned blastocysts but had no positive effects on the rate of cloned embryos development to term (Sampaio *et al.* 2020). Likewise, chetomin, a fungal secondary metabolite

reported to inhibit the trimethylation on histone 3 lysine 9 (H3K9me3), proved ineffective in horse SCNT embryos (Damasceno Teixeira *et al.* 2019). Lastly, a SCNT study carried out in rhesus macaque (*Macaca mulatta*) transplanting fetal and adult cells (fibroblasts and cumulus cells, respectively) into enucleated oocytes enriched with *Kdm4d* mRNA and treated with TSA after virus-induced fusion brought no major advancements. Two live offspring were delivered from fetal cells. The two infants derived from cumulus cells had to be delivered by cesarian section, and both died within 3 days because of respiratory distress. It is a great pity that no data on the placental phenotype and necropsy were reported (Liu *et al.* 2018). Therefore, a combined treatment with H3K9 demethylation and TSA brought no significant improvements when somatic cells were used for SCNT. However, it must be said that the number of available replicates is too limited to draw any definitive conclusions.

Current applications of SCNT in large animals and pets

What has been presented above about the state-of-the-art in nuclear reprogramming strategies in large animals led to our partial conclusion that no effective nuclear reprogramming strategies are available. Yet, working with large numbers of embryos allows for the application of cloning in several commercial settings, including multiplication of livestock with particular genetic characteristics, production of cloned dogs and cats, even post mortem, reproduction of castrated animals, usually horses, and production of animal models for human pathologies.

Cloning for the multiplication of livestock with particular genetic characteristics is mainly confined to cattle and swine farming. Typically, only cattle of high genetic value, mainly of beef breeds, are reproduced through SCNT. The most active companies are operating in the USA. Of these, Transova (<https://transova.com>) has to its credit the production of thousands of clones. In fact, the US Food and Drug Agency (FDA) gave a favorable opinion on the consumption of cloned animal products. Another strong player is China, where a private cattle and pigs cloning company, Boyalife (<https://www.boyalifegroup.com>), has just been founded as part of a network with Chinese universities and research centers. Boyalife is extending to Hong Kong and the USA. The situation in Europe is more difficult given that the European Parliament banned in September 2015 the import and consumption of food products derived from cloned animals, indicating a strong negative perception of cloning.

Dogs and cats were the last species to be cloned (Shin *et al.* 2002, Lee *et al.* 2005). Their importance as companion animals has fueled the emergence of cloning companies, active primarily in cases of terminally ill or

even deceased animals. For that reason, these companies offer biobanking services of cells sampled from pets, to be used eventually to replace them in case of death. Again, the leading companies in this sector are in the USA, such as Viagenpets (<https://viagenpets.com/>) and China (e.g. Sinogene; <https://www.sinogene.org>).

The reproduction of castrated animals through SCNT applies primarily to sport horses. Being an asexual reproduction method, cloning offers the possibility to reproduce champions castrated before starting their sports activities. The first cloned horse was produced in Italy by Avantea (Galli *et al.* 2003). Unlike other horse breeds, such as the English thoroughbred, reproductive technologies, including cloning, are allowed in polo horses. Polo riders often change horses during the game, so the performances of the different mounts are important. A few years ago, information about an Argentinian team that regularly used cloned horses, six to be exact, all derived from a famous mare, Cuatetera, hit the news. The team's success has established cloning as a way to multiply champion racing horses, a trend that is progressively spreading to high-income countries. In addition to the Italian Avantea, other companies that deal with commercial equine cloning are Crestview Genetics and the Argentinian Kheiron, the last with approximately 200 live clones produced (http://www.kheiron-biotech.com/index_en.html).

Traditionally, the study of the onset and treatment of various human diseases use transgenic mouse models. These are transgenic mouse lines in which the gene(s) responsible for a given human pathology has been inserted/mutated. Although the advantages deriving from these models are numerous, the mouse has intrinsic limitations such as a short life span and small size. In fact, if these models are useful when striving to understand the disease onset, they are not much so in the development of treatments, including surgery, for the disease. Cloning has made it possible to produce suitable animal models of human pathologies, most often pigs but also sheep. This was made possible thanks to the development of efficient genome editing tools, also applicable to somatic cells. Operationally speaking, it involves inserting the mutated gene of interest or modifying or removing an endogenous one. For example, the muscular dystrophy gene could be inserted through genome editing methods such as CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated protein 9) into cells cultured *in vitro*. The transformed cells, selected by appropriate culture conditions, are transferred into enucleated oocytes, and the resulting embryos are transplanted into suitable foster mothers for development to term (Lee *et al.* 2020). The animals thus generated will express the mutated gene and therefore the resulting pathology. Currently, pig models are available for many degenerative and non-degenerative neurological, endocrinologic, and muscular disorders

(for review see, [Holm et al. 2016](#), [Whitelaw et al. 2016](#), [Hoffe & Holahan 2019](#)). Noteworthy is the production of a sheep model of cystic fibrosis ([Fan et al. 2018](#)).

Still in the context of animal models, pigs 'humanized' immunologically by cloning with genetically modified cells could be used to produce organs, such as liver, heart, and kidneys, for transplantation into human patients ([Whitelaw et al. 2016](#)). This research branch is progressing rapidly, although many are the roadblock to overcome on the way to clinical applications ([Reichart et al. 2020](#)). Besides immunological rejection, additional complications are represented by the risk of cross-species transmission of Porcine Endogenous RetroVirus (PERV; [Yang & Wu 2018](#)). The use of PERV knockout pig cell lines might alleviate this infectious risk ([Niu et al. 2017](#)). However, such an approach raised the concerns of possible cryptic mutations resulting from the massive genome editing required. Lastly, even allogenic transplant size must be finely considered ([Hinrichs et al. 2020](#)).

Of note, 'humanized' pigs have been recently deployed to fight the ongoing COVID-19 pandemic. Double knockout pigs, lacking CMP-N-acetylneuraminic acid hydroxylase (*CMAH*) and α 1,3-galactosyl-transferase (*GGTA1*) genes that are needed to produce glyco-humanized polyclonal antibodies (GH-pAb) without the Neu5Gc and α -Gal epitopes, were immunized with the SARS-CoV-2 spike Receptor-Binding Domain (RBD). A robust hyperimmune response, with anti-SARS-CoV-2 end-titer binding dilutions of over one to a million, was found ([Vanhove et al. 2021](#)).

Alternative nuclear reprogramming strategies

The picture described previously, along with the verification that the numbers of SCNT reports dealing with large animals by far surpasses that in mice ([Fig. 1](#)), stresses the urgent need for an efficient and safe SCNT in large animals.

The current axiom is that, even in mice, the best protocols have not entirely eliminated the SCNT-associated placental abnormalities. An exception is SCNT with genetically modified donor cells taken from a mouse knockout (KO) for the *Sfmbt2* locus that codes for a miRNA cluster ([Inoue et al. 2020](#)). Moreover, 'birth rate' in mice means pup delivery by cesarian section ([Ogura 2020](#)). Clearly, the use of genetically modified cell lines or cesarian section as a routine in large animals is not an option. Therefore, in-depth studies are required to develop radical and universal nuclear reprogramming strategies.

Suitable directions for evolving nuclear reprogramming strategies

In our experience, confirmed by most of the published data, placental abnormalities are common features in

cloned large animal offspring, although with a milder phenotype in cloned pigs ([Constant et al. 2006](#), [Loi et al. 2006](#), [Palmieri et al. 2008](#), [Pozor et al. 2016](#), [Ao et al. 2019](#)). The penetrance of the phenotype spans from a life-threatening disease of the foster mother carrying the cloned conceptus, like hydro-allantois, to milder ones, where cardiac and liver pathological signatures are correlated to compromised kidney function. Osmotic imbalances, causing an abnormal accumulation of amniotic and allantoic fluids, ultimately impede fetal urine drainage, resulting in a systemic uremic syndrome that first affects the kidneys and then upstream organs in a domino-like fashion ([Loi et al. 2006](#)).

This is not surprising. The placental genes are expressed in a unique, disposable, extracorporeal organ, with a much shorter lifespan than the soma. The organ contains cells with a weird chromosomal constitution, including aneuploidy, multinucleation, and DNA endo-reduplication ([Weier et al. 2005](#), [Hayakawa et al. 2018](#), [Bhattacharya et al. 2020](#)). These properties, known as Partially Methylated Domains (PMDs), while conferring proliferative advantages to placental cells in this cancer-like organ, are epigenetic hallmarks in cancer ([Decato et al. 2020](#)). However, this unique organ requires a formidable safety device to hide those genes from the transcriptional machinery in somatic cells. Thus, placental genes, present in all somatic cells, as established by the Dolly's principle of 'genome totipotency,' must be 'double-locked' and made inaccessible for transcription. As a result, placental genes are only superficially affected by the nuclear reprogramming machinery when using the approaches so far reported.

There is an urgent need to radically change our vision about nuclear reprogramming and seek inspiration from the most efficient and universally adopted nuclear transfer device – the spermatozoa and its natural 'recipient,' the oocyte.

Paternal-specific nuclear reprogramming

The preparation for immortality, ensured by establishing a totipotency state in the male and female germlines, takes several months or years, depending on the species. Our view is that we need to mimic, even partially, the epigenetic/chromosome organization in these two highly specialized cells if we wish to find innovative solutions for nuclear reprogramming. Following this line of thought, we started a decade ago to explore the conversion of somatic cell nuclei into a spermatid-like structure. The approach we initially followed was a progressive expression of testis-specific proteins in somatic cells, sheep fibroblasts. The first trials led nowhere. However, inspired by male gametogenesis in other animal models ([Martínez-Soler et al. 2007](#)), we attempted to directly express protamine 1 in sheep fibroblasts. The results were surprising as, 48 h after transfection, a sizeable

Figure 2 Nuclear remodeling in sheep fibroblasts expressing GFP tagged human Protamine 1 (left, DNA- DAPI; center, hPrm1-GFP; right, merge).

proportion of the interphase nuclei compacted into a shape reminiscent of spermatid nuclei (Fig. 2). Chip Seq analysis showed that the protamine 1 was bound to large nuclear domains, and, most importantly, the genome protaminization was fully reversible after nuclear transfer (Iuso *et al.* 2015). Furthermore, the blastocyst rate in embryos reconstructed with protaminized somatic cells was twice as high as the control, untransfected cells. Although the final proof, the production of cloned offspring, is still missing, we can state with high certainty that protaminization confers improved development up to the blastocyst stage (Czernik *et al.* 2016).

The rationale of this approach is that while the oocyte has no molecular tools to unravel the large-scale genome organization in nucleosomally organized, differentiated cells, the protaminized nucleus brings a unique DNA format similar to that delivered by the fertilizing spermatozoa, which the oocyte can handle. More studies are required to optimize the somatic nuclei protaminization approach. Ideally, the perfect protocol should lead to a protamine-to-nucleosome ratio similar to that typically found in the spermatozoa of the studied species (Yoshida *et al.* 2018).

Maternal specific nuclear reprogramming

Oocyte chromosomes, just like the paternal ones, prepare for totipotency. Indeed, the maternal chromatin must be streamlined in preparation for fertilization.

Very little is known about the reprogramming of oocyte chromosomes during the final maturation stage. There is a great deal of information about meiotic recombination through crossing over (Hughes *et al.* 2018) and epigenetic modifications in preparation for meiosis (De La Fuente 2014) but not about the preparations for totipotency.

A nuclear reprogramming strategy cannot ignore the special features and large-scale nuclear reprogramming occurring in fully grown germinal vesicle (GV) oocytes in preparation for totipotency (Fig. 3). Again, most basic research was performed on mice. When oocytes reach their full size, their chromatin undergoes a marked change and condenses around the nucleolus to become the so-called surrounded nucleus (SN)-type oocytes (Zuccotti *et al.* 1995). Functional studies have shown that this transition is necessary for the oocyte to gain its full developmental competence and is accompanied by a marked decrease in RNA polymerase I and II transcriptional activity (Fair *et al.* 1995, Bouniol-Baly *et al.* 1999, De La Fuente 2006, Inoue *et al.* 2008, Dumdie *et al.* 2018). The details of the process remain elusive; however, the chromatin condensation seems to be linked to histone deacetylase activity since it can be reverted by TSA treatment (De La Fuente *et al.* 2004). Nevertheless, TSA treatment does not influence the transcriptional activity, suggesting the presence of a different mechanism behind the oocyte-specific transcriptional program termination before the transition

Figure 3 Time-scale schematic representation of oocyte growth and nuclear remodeling.

Figure 4 The process of selective enucleation coupled with nuclear transfer. (A) First, a somatic nucleus typically derived from a cumulus cell (arrow) is transferred into a germinal vesicle stage oocyte, which still contains its original nucleus (germinal vesicle, GV) with a prominent nucleolus precursor body (NPB). (B) In a next step, the oocyte is selectively enucleated. The nuclear envelope (NE) and the chromatin in slowly pulled out by a fine pipette. The soluble GV content and the NPBs are expelled into the cytoplasm and available to be incorporated by the somatic nucleus already present in the cytoplasm. (C) After 20 h, the remodeled somatic nuclei (SCNT-SE, arrows) are morphologically very similar to control germinal stage oocytes (GV). (D) The uptake of histone H3.3 to the remodeled somatic nucleus. Top image shows the localization of this histone variant in the chromatin of the germinal vesicle (GV). Note that H3.3 levels are very low in cumulus somatic cells, which were used as donors. After an overnight incubation and remodeling, this histone variant is efficiently incorporated into the somatic chromatin, bottom. The samples were extracted upon fixation, thus, only incorporated H3.3 is detected. Scale bar, 50 μ m.

to totipotency (De La Fuente *et al.* 2004). This is likely achieved by the dissociation and degradation of RNA polymerase II (Fulka *et al.* 2009, Abe *et al.* 2010).

The published data on mature oocytes showed that they have a highly accessible chromatin (Lu *et al.* 2016, Gu *et al.* 2019), enriched by several histone variants. These include the linker histone variants H1FOO, H3.3, or TH2A/TH2B (Tanaka *et al.* 2001, Akiyama *et al.* 2011, Shinagawa *et al.* 2014). The accumulation of these specialized histones at high levels seems to be a universal feature of oocytes (McGraw *et al.* 2006, Zhang *et al.* 2018) and, at least in mice, was shown to have beneficial effects on reprogramming (Gao *et al.* 2004, Shinagawa *et al.* 2014, Wen *et al.* 2014a). However, the simple presence of these histone variants might not be sufficient to induce full totipotency, as neither H3.3 nor TH2A/TH2B is exclusively expressed in oocytes. Therefore, other specialized chromatin factors, such as histone chaperones and remodeling complexes, likely give the oocyte chromatin its unique features (Zhang *et al.* 2016, 2020a, Ooga *et al.* 2018).

Our knowledge of oocyte chromatin modifications leading to nuclear totipotency is limited. One possible explanation for this lack of knowledge might be that since the production of Dolly, the oocyte potential to restore totipotency has been studied exclusively with nuclear reprogramming of somatic cells in mind. However, this event occurs in mature metaphase II oocytes after artificial activation, concomitant with DNA replication. Post-activation somatic cell nuclear remodeling/reprogramming works but again drifts significantly from the physiological path, where both oocyte and

spermatozoa undergo nuclear reprogramming in a replication-independent fashion. Missing are studies addressing the molecular mechanism leading to totipotency to the resident chromosomes in oocytes.

Insights from germinal vesicles remodeling of somatic cells nuclei

More informative in this respect are studies in which mouse somatic nuclei were transplanted into the GV, the giant nucleus of an immature *Xenopus* oocyte (Miyamoto *et al.* 2018). Under these conditions, it is possible to detect changes in chromatin accessibility, induced in a replication-independent manner, just like during oocyte-specific reprogramming. Large-scale chromatin modifications were captured using a modified Assay for Transposase-Accessible Chromatin Sequencing (ATAC-seq) (Buenrostro *et al.* 2013). The assay revealed open chromatin regions by exploiting the Tn5 transposons capacity to insert into accessible chromatin domains. The data showed that somatic cell nuclei undergo extensive transcriptional reprogramming toward an oocyte-like state within 2 days, without replication. Expectedly, genes with a pre-existing open structure were easily reactivated, while only a few of the genes that typically become accessible only after nuclear transfer acquired an open chromatin state. Increased nuclear actin polymerization due to overexpression of *Toca1/Fnbp1l* seems to play a primary role in inducing chromatin 3D rearrangement (Miyamoto *et al.* 2011). These findings are enlightening in many ways and more informative than the available post-nuclear transfer data

Figure 5 Schematic overview of the current (A) and suggested (B and C) strategies for nuclear reprogramming.

on nuclear reprogramming. Unfortunately, the size and organization of mammalian oocytes markedly differ from those of *Xenopus*, preventing us from repeating such an important study in mammals. However, a compromise might be found in using Selectively Enucleated GV (SEGV) oocytes. Selective enucleation was first described by Modlinski in 1975 (Modliński 1975) and is used to obtain cytoplasts depleted of chromatin, tDNA, DNA-bound factors, and the nuclear envelope (Gręda *et al.* 2006). This method is somewhat equivalent to oocyte fractionation and allows the analysis of the reprogramming processes that occurs primarily under the influence of the soluble nuclear fraction found in the GV. In some way, injecting somatic nuclei into SEGV oocytes mimics, with a good approximation, the *Xenopus* GV nuclear transfer experiment (Fulka *et al.* 2019). The somatic nuclei exposure time to the SEGV oocyte cytoplasm can be easily controlled by culturing them in the presence of the meiotic progression inhibitor dbcAMP (Fulka *et al.* 2019). Thus, somatic nuclei can remain in the SEGV for up to 20 h, a time frame similar to the *Xenopus* experiments (Miyamoto *et al.* 2018). Using this model, long-range replication-independent somatic cell chromatin modifications can also be monitored in other species. Initial results indicated that the somatic nucleus undergoes an incredible nuclear remodeling, gaining a morphology and size similar to control GV-stage oocytes (Fig. 4), anticipated by transcriptional and replication silencing of the transferred nucleus (Fulka *et al.* 2019). The epigenetic modification so far detected indicates enrichment of histone variant H3.3, which is essential for normal development and indicative of an extensive reprogramming in the somatic

chromatin (Fulka *et al.* 2019, Fig. 4). However, the soluble GV fraction seems to be rather inefficient in replacing somatic histones H3.1/H3.2, typically found in closed chromosomal domains (Wen *et al.* 2014a,b). We speculate that this persistence of H3.1/H3.2 is caused by the lack of replication that does not occur in this type of cytoplast. SEGV cytoplasts just started to deliver the initial data, confirming their importance as an unparalleled model to study nuclear reprogramming under physiological conditions. Another sub-nuclear compartment to consider in nuclear remodeling studies are the atypical nucleoli present in oocytes and early embryos. Initial experiments have shown that the oocyte nucleolus is essential for successful development following SCNT (Ogushi *et al.* 2008), likely impacting the 3D genome organization and remodeling of some specific sequences such as the major and minor satellites (Fulka & Langerova 2014).

Concluding remarks

Ideally, an efficient nuclear reprogramming strategy should significantly increase the term development rate, eliminate placental abnormalities, and be applicable to all species. As remarked earlier, the Achilles' heel of current procedures is the difficulties in controlling nuclear reprogramming of somatic genes. The resistance is particularly severe in extra-somatic placental genes. Twenty-five years after Dolly was born is a remarkable turning point. The lesson gained from the over three thousand published SCNT reports is that we need to radically change our approach.

Put simply, we need to reverse our focus, and instead of insisting on epi/genetic modification occurring during post-nuclear transfer genome reprogramming, we need to learn how maternal and paternal alleles are prepared for fertilization, and hence for totipotency. Research on the spermatid epigenetic remodeling during the transition to mature spermatozoa is advanced and comprehensively described in a recent reviews (Meyer *et al.* 2017); lesser knowledge is available on the female gamete. Indeed, profound, large-scale chromatin modification takes place during the last nuclear maturation phase of the follicle-enclosed oocyte (Fig. 4). Luckily, the available technologies provide unique insights into chromatin organization at different levels. The main structural ‘units’ comprise chromosome territories, compartments A/B, topologically associated domains (TADs), and loops, all help shape the 3D structure, and some are likely cell-type specific. These techniques will help us appreciate the unique chromatin organization in oocytes (Flyamer *et al.* 2017, Ke *et al.* 2017, Chen *et al.* 2020, Zhang *et al.* 2020b). The gained information will be extremely useful in providing us with data on the epigenetic format we need to confer on the maternal alleles in somatic cells (Fig. 5).

If we wish to enhance the cloning process in large animals, the key prerequisite is a detailed understanding of oocyte nuclear reprogramming when preparing for fertilization. Unfortunately, one of the negative legacies of Dolly is the ethical aftermath that has instilled a negative perception, especially in Europe, rendering funding for SCNT challenging to obtain. This negative perception is unjustified, for robust reports on the normalcy of cloned animals are in place (Sinclair *et al.* 2016). We believe that 25 years after the birth of Dolly, we have at our disposal unprecedented technological and analytical tools, knowledge, and several proof-of-principal reports that the development of a safe and effective SCNT procedure can be achieved in the medium term.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work received funding from the European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreements No. 734434. L P and P L were supported by the project ‘DEMETRA’ (MIUR) Department of Excellence (2018–2022). M C and L P acknowledge the support from the National Science Centre, Poland through grant No. 2016/21/D/NZ3/02610 (Sonata) and 2019/35/B/NZ3/02856 (Opus). H F and H F Jr. are funded by the Czech

Science Foundation (GACR) 20-04465S. ORCID 0000-0001-7414-5024 (H F). The Authors warmly thank Dr Joseph Saragusty for the extraordinary editing work done on the manuscript.

Author contribution statement

All authors have contributed to write this review article.

References

- Abe K-I, Inoue A, Suzuki MG & Aoki F 2010 Global gene silencing is caused by the dissociation of RNA polymerase II from DNA in mouse oocytes. *Journal of Reproduction and Development* **56** 502–507. (<https://doi.org/10.1262/jrd.10-068a>)
- Akiyama T, Suzuki O, Matsuda J & Aoki F 2011 Dynamic replacement of histone H3 variants reprograms epigenetic marks in early mouse embryos. *PLoS Genetics* **7** e1002279. (<https://doi.org/10.1371/journal.pgen.1002279>)
- Ao Z, Wu X, Zhou J, Gu T, Wang X, Shi J, Zhao C, Cai G, Zheng E, Liu D *et al.* 2019 Cloned pig fetuses exhibit fatty acid deficiency from impaired placental transport. *Molecular Reproduction and Development* **86** 1569–1581. (<https://doi.org/10.1002/mrd.23242>)
- Bhattacharya B, Home P, Ganguly A, Ray S, Ghosh A, Islam MR, French V, Marsh C, Gunewardena S, Okae H *et al.* 2020 Atypical protein kinase C ι (PKC ι) ensures mammalian development by establishing the maternal-fetal exchange interface. *PNAS* **117** 14280–14291. (<https://doi.org/10.1073/pnas.1920201117>)
- Bouniol-Baly C, Hamraoui L, Guibert J, Beaujean N, Szöllösi MS & Debey P 1999 Differential transcriptional activity associated with chromatin configuration in fully grown mouse germinal vesicle oocytes. *Biology of Reproduction* **60** 580–587. (<https://doi.org/10.1095/biolreprod60.3.580>)
- Buenrostro JD, Giresi PG, Zaba LC, Chang HY & Greenleaf WJ 2013 Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nature Methods* **10** 1213–1218. (<https://doi.org/10.1038/nmeth.2688>)
- Campbell KHS, Loi P, Cappai P & Wilmut I 1994 Improved development to blastocyst of ovine nuclear transfer embryos reconstructed during the presumptive S-phase of enucleated activated oocytes. *Biology of Reproduction* **50** 1385–1393. (<https://doi.org/10.1095/biolreprod50.6.1385>)
- Campbell KH, Loi P, Otaegui PJ & Wilmut I 1996a Cell cycle co-ordination in embryo cloning by nuclear transfer. *Reviews of Reproduction* **1** 40–46. (<https://doi.org/10.1530/ror.0.0010040>)
- Campbell KH, McWhir J, Ritchie WA & Wilmut I 1996b Sheep cloned by nuclear transfer from a cultured cell line. *Nature* **380** 64–66. (<https://doi.org/10.1038/380064a0>)
- Chen M, Zhu Q, Li C, Kou X, Zhao Y, Li Y, Xu R, Yang L, Yang L, Gu L *et al.* 2020 Chromatin architecture reorganization in murine somatic cell nuclear transfer embryos. *Nature Communications* **11** 1813. (<https://doi.org/10.1038/s41467-020-15607-z>)
- Constant F, Guillomot M, Heyman Y, Vignon X, Laigre P, Servely JL, Renard JP & Chavatte-Palmer P 2006 Large offspring or large placenta syndrome? Morphometric analysis of late gestation bovine placentomes from somatic nuclear transfer pregnancies complicated by hydrallantois. *Biology of Reproduction* **75** 122–130. (<https://doi.org/10.1095/biolreprod.106.051581>)
- Czernik M, Iuso D, Toschi P, Khochbin S & Loi P 2016 Remodeling somatic nuclei via exogenous expression of protamine 1 to create spermatid-like structures for somatic nuclear transfer. *Nature Protocols* **11** 2170–2188. (<https://doi.org/10.1038/nprot.2016.130>)
- Damasceno Teixeira TV, Fry RC, McKinnon A, Fry KL, Kelly JM, Verma PJ, Burden C, Salamone DF & Gambini A 2019 Targeting epigenetic nuclear reprogramming in aggregated cloned equine embryos. *Reproduction, Fertility, and Development* **31** 1885–1893. (<https://doi.org/10.1071/RD19239>)
- De La Fuente R 2006 Chromatin modifications in the germinal vesicle (GV) of mammalian oocytes. *Developmental Biology* **292** 1–12. (<https://doi.org/10.1016/j.ydbio.2006.01.008>)

- De La Fuente R 2014 Histone deacetylation: establishing a meiotic histone code. *Cell Cycle* **13** 879–880. (<https://doi.org/10.4161/cc.28214>)
- De La Fuente R, Viveiros MM, Burns KH, Adashi EY, Matzuk MM & Eppig JJ 2004 Major chromatin remodeling in the germinal vesicle (GV) of mammalian oocytes is dispensable for global transcriptional silencing but required for centromeric heterochromatin function. *Developmental Biology* **275** 447–458. (<https://doi.org/10.1016/j.ydbio.2004.08.028>)
- Decato BE, Qu J, Ji X, Wagenblast E, Knott SRV, Hannon GJ & Smith AD 2020 Characterization of universal features of partially methylated domains across tissues and species. *Epigenetics and Chromatin* **13** 39. (<https://doi.org/10.1186/s13072-020-00363-7>)
- Dumdie JN, Cho K, Ramaiah M, Skarbrevik D, Mora-Castilla S, Stumpo DF, Lykke-Andersen J, Laurent LC, Blackshear PF, Wilkinson MF *et al.* 2018 Global transcriptional silencing and developmental competence in the oocyte mediated by the mRNA decay activator ZFP36L2. *Developmental Cell* **44** 392.e7–402.e7.
- Fair T, Hyttel P & Greve T 1995 Bovine oocyte diameter in relation to maturational competence and transcriptional activity. *Molecular Reproduction and Development* **42** 437–442. (<https://doi.org/10.1002/mrd.1080420410>)
- Fan Z, Perisse IV, Cotton CU, Regouski M, Meng Q, Domb C, Van Wettere AJ, Wang Z, Harris A, White KL *et al.* 2018 A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene. *JCI Insight* **3** e123529. (<https://doi.org/10.1172/jci.insight.123529>)
- First NL 1990 New animal breeding techniques and their application. *Journal of Reproduction and Fertility: Supplement* **41** 3–14.
- Flyamer IM, Gassler J, Imakaev M, Brandão HB, Ulianov SV, Abdennur N, Razin SV, Mirny LA & Tachibana-Konwalski K 2017 Single-nucleus Hi-C reveals unique chromatin reorganization at oocyte-to-zygote transition. *Nature* **544** 110–114. (<https://doi.org/10.1038/nature21711>)
- Fulka H & Langerova A 2014 The maternal nucleolus plays a key role in centromere satellite maintenance during the oocyte to embryo transition. *Development* **141** 1694–1704. (<https://doi.org/10.1242/dev.105940>)
- Fulka H, Novakova Z, Mosko T & Fulka J 2009 The inability of fully grown germinal vesicle stage oocyte cytoplasm to transcriptionally silence transferred transcribing nuclei. *Histochemistry and Cell Biology* **132** 457–468. (<https://doi.org/10.1007/s00418-009-0625-x>)
- Fulka H, Ogura A, Loi P & Fulka Jr J 2019 Dissecting the role of the germinal vesicle nuclear envelope and soluble content in the process of somatic cell remodelling and reprogramming. *Journal of Reproduction and Development* **65** 433–441. (<https://doi.org/10.1262/jrd.2019-017>)
- Galli C, Lagutina I, Crotti G, Colleoni S, Turini P, Ponderato N, Duchi R & Lazzari G 2003 Pregnancy: a cloned horse born to its dam twin. *Nature* **424** 635. (<https://doi.org/10.1038/424635a>)
- Gao S, Chung YG, Parseghian MH, King GJ, Adashi EY & Latham KE 2004 Rapid H1 linker histone transitions following fertilization or somatic cell nuclear transfer: evidence for a uniform developmental program in mice. *Developmental Biology* **266** 62–75. (<https://doi.org/10.1016/j.ydbio.2003.10.003>)
- Gręda P, Karasiewicz J & Modliński JA 2006 Mouse zygotes as recipients in embryo cloning. *Reproduction* **132** 741–748. (<https://doi.org/10.1530/rep.1.01204>)
- Gu C, Liu S, Wu Q, Zhang L & Guo F 2019 Integrative single-cell analysis of transcriptome, DNA methylome and chromatin accessibility in mouse oocytes. *Cell Research* **29** 110–123. (<https://doi.org/10.1038/s41422-018-0125-4>)
- Gurdon JB, Laskey RA & Reeves OR 1975 The developmental capacity of nuclei transplanted from keratinized skin cells of adult frogs. *Journal of Embryology and Experimental Morphology* **34** 93–112.
- Hayakawa K, Terada K, Takahashi T, Oana H, Washizu M & Tanaka S 2018 Nucleosomes of polyploid trophoblast giant cells mostly consist of histone variants and form a loose chromatin structure. *Scientific Reports* **8** 5811. (<https://doi.org/10.1038/s41598-018-23832-2>)
- Hinrichs A, Riedel EO, Klymiuk N, Blutke A, Kemter E, Längin M, Dahlhoff M, Keßler B, Kurome M, Zakhartchenko V *et al.* 2020 Growth hormone receptor knockout to reduce the size of donor pigs for preclinical xenotransplantation studies. *Xenotransplantation* **25** e12664. (<https://doi.org/10.1111/xen.12664>)
- Hoffe B & Holahan MR 2019 The use of pigs as a translational model for studying neurodegenerative diseases. *Frontiers in Physiology* **10** 838. (<https://doi.org/10.3389/fphys.2019.00838>)
- Holm IE, Alstrup AK & Luo Y 2016 Genetically modified pig models for neurodegenerative disorders. *Journal of Pathology* **238** 267–287. (<https://doi.org/10.1002/path.4654>)
- Hosseini SM, Dufort I, Nieminen J, Moulavi F, Ghanaei HR, Hajian M, Jafarpour F, Forouzanfar M, Gourbai H, Shahverdi AH *et al.* 2016 Epigenetic modification with trichostatin A does not correct specific errors of somatic cell nuclear transfer at the transcriptomic level; highlighting the non-random nature of oocyte-mediated reprogramming errors. *BMC Genomics* **17** 16. (<https://doi.org/10.1186/s12864-015-2264-z>)
- Huan Y, Zhu J, Huang B, Mu Y, Kong Q & Liu Z 2015 Trichostatin A rescues the disrupted imprinting induced by somatic cell nuclear transfer in pigs. *PLoS ONE* **10** e0126607. (<https://doi.org/10.1371/journal.pone.0126607>)
- Hughes SE, Miller DE, Miller AL & Hawley RS 2018 Female meiosis: synapsis, recombination, and segregation in *Drosophila melanogaster*. *Genetics* **208** 875–908. (<https://doi.org/10.1534/genetics.117.300081>)
- Inoue A, Nakajima R, Nagata M & Aoki F 2008 Contribution of the oocyte nucleus and cytoplasm to the determination of meiotic and developmental competence in mice. *Human Reproduction* **23** 1377–1384. (<https://doi.org/10.1093/humrep/den096>)
- Inoue K, Ogonuki N, Kamimura S, Inoue H, Matoba S, Hirose M, Honda A, Miura K, Hada M, Hasegawa A *et al.* 2020 Loss of H3K27me3 imprinting in the Sfmbt2 miRNA cluster causes enlargement of cloned mouse placentas. *Nature Communications* **11** 2150. (<https://doi.org/10.1038/s41467-020-16044-8>)
- Iuso D, Czernik M, Toschi P, Fidanza A, Zacchini F, Feil R, Curtet S, Buchou T, Shiota H, Khochbin S *et al.* 2015 Exogenous expression of human protamine 1 (hPrm1) remodels fibroblast nuclei into spermatid-like structures. *Cell Reports* **13** 1765–1771. (<https://doi.org/10.1016/j.celrep.2015.10.066>)
- Ke Y, Xu Y, Chen X, Feng S, Liu Z, Sun Y, Yao X, Li F, Zhu W, Gao L *et al.* 2017 3D chromatin structures of mature gametes and structural reprogramming during mammalian embryogenesis. *Cell* **170** 367.e20–381.e20. (<https://doi.org/10.1016/j.cell.2017.06.029>)
- Kishigami S, Mizutani E, Ohta H, Hikichi T, Thuan NV, Wakayama S, Bui HT & Wakayama T 2006 Significant improvement of mouse cloning technique by treatment with trichostatin A after somatic nuclear transfer. *Biochemical and Biophysical Research Communications* **340** 183–189. (<https://doi.org/10.1016/j.bbrc.2005.11.164>)
- Lee BC, Kim MK, Jang G, Oh HJ, Yuda F, Kim HJ, Hossein MS, Kim JJ, Kang SK, Schatten G *et al.* 2005 Dogs cloned from adult somatic cells. *Nature* **436** 641. (<https://doi.org/10.1038/436641a>)
- Lee K, Uh K & Farrell K 2020 Current progress of genome editing in livestock. *Theriogenology* **150** 229–235. (<https://doi.org/10.1016/j.theriogenology.2020.01.036>)
- Liu Z, Cai Y, Wang Y, Nie Y, Zhang C, Xu Y, Zhang X, Lu Y, Wang Z, Poo M *et al.* 2018 Cloning of macaque monkeys by somatic cell nuclear transfer. *Cell* **172** 881.e7–887.e7. (<https://doi.org/10.1016/j.cell.2018.01.020>)
- Loi P, Clinton M, Vackova I, Fulka J, Feil R, Palmieri C, Della Salda L & Ptak G 2006 Placental abnormalities associated with post-natal mortality in sheep somatic cell clones. *Theriogenology* **65** 1110–1121. (<https://doi.org/10.1016/j.theriogenology.2005.07.016>)
- Lu F, Liu Y, Inoue A, Suzuki T, Zhao K & Zhang Y 2016 Establishing chromatin regulatory landscape during mouse preimplantation development. *Cell* **165** 1375–1388. (<https://doi.org/10.1016/j.cell.2016.05.050>)
- Maalouf WE, Liu Z, Brochard V, Renard JP, Debey P, Beaujean N & Zink D 2009 Trichostatin A treatment of cloned mouse embryos improves constitutive heterochromatin remodeling as well as developmental potential to term. *BMC Developmental Biology* **9** 11. (<https://doi.org/10.1186/1471-213X-9-11>)
- Martínez-Soler F, Kurtz K, Ausió J & Chiva M 2007 Transition of nuclear proteins and chromatin structure in spermiogenesis of *Sepia officinalis*. *Molecular Reproduction and Development* **74** 360–370. (<https://doi.org/10.1002/mrd.20515>)
- Matoba S, Inoue K, Kohda T, Sugimoto M, Mizutani E, Ogonuki N, Nakamura T, Abe K, Nakano T, Ishino F *et al.* 2011 RNAi-mediated knockdown of Xist can rescue the impaired postimplantation development of cloned mouse embryos. *PNAS* **108** 20621–20626. (<https://doi.org/10.1073/pnas.1112664108>)

- Matoba S, Liu Y, Lu F, Iwabuchi KA, Shen L, Inoue A & Zhang Y 2014 Embryonic development following somatic cell nuclear transfer impeded by persisting histone methylation. *Cell* **159** 884–895. (<https://doi.org/10.1016/j.cell.2014.09.055>)
- McGraw S, Vigneault C, Tremblay K & Sirard MA 2006 Characterization of linker histone H1FOO during bovine in vitro embryo development. *Molecular Reproduction and Development* **73** 692–699. (<https://doi.org/10.1002/mrd.20448>)
- Meyer RG, Ketchum CC & Meyer-Ficca ML 2017 Heritable sperm chromatin epigenetics: a break to remember. *Biology of Reproduction* **97** 784–797. (<https://doi.org/10.1093/biolre/iox137>)
- Miyamoto K, Pasque V, Jullien J & Gurdon JB 2011 Nuclear actin polymerization is required for transcriptional reprogramming of Oct4 by oocytes. *Genes and Development* **25** 946–958. (<https://doi.org/10.1101/gad.615211>)
- Miyamoto K, Nguyen KT, Allen GE, Jullien J, Kumar D, Otani T, Bradshaw CR, Livesey FJ, Kellis M & Gurdon JB 2018 Chromatin accessibility impacts transcriptional reprogramming in oocytes. *Cell Reports* **24** 304–311. (<https://doi.org/10.1016/j.celrep.2018.06.030>)
- Modliński JA 1975 Haploid mouse embryos obtained by microsurgical removal of one pronucleus. *Journal of Embryology and Experimental Morphology* **33** 897–905.
- Narbonne P, Miyamoto K & Gurdon JB 2012 Reprogramming and development in nuclear transfer embryos and in interspecific systems. *Current Opinion in Genetics and Development* **22** 450–458. (<https://doi.org/10.1016/j.gde.2012.09.002>)
- Niu D, Wei HJ, Lin L, George H, Wang T, Lee IH, Zhao HY, Wang Y, Kan Y, Shrock E *et al.* 2017 Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. *Science* **357** 1303–1307. (<https://doi.org/10.1126/science.aan4187>)
- Ogura A 2020 How to improve mouse cloning. *Theriogenology* **150** 215–220. (<https://doi.org/10.1016/j.theriogenology.2020.01.038>)
- Ogura A, Inoue K & Wakayama T 2013 Recent advancements in cloning by somatic cell nuclear transfer. *Philosophical Transactions of the Royal Society of London: Series B, Biological Sciences* **368** 20110329. (<https://doi.org/10.1098/rstb.2011.0329>)
- Ogushi S, Palmieri C, Fulka H, Saitou M, Miyano T & Fulka J 2008 The maternal nucleolus is essential for early embryonic development in mammals. *Science* **319** 613–616. (<https://doi.org/10.1126/science.1151276>)
- Ooga M, Funaya S, Hashioka Y, Fujii W, Naito K, Suzuki MG & Aoki F 2018 Chd9 mediates highly loosened chromatin structure in growing mouse oocytes. *Biochemical and Biophysical Research Communications* **500** 583–588. (<https://doi.org/10.1016/j.bbrc.2018.04.105>)
- Palmieri C, Loi P, Ptak G & Della Salda L 2008 Review paper: a review of the pathology of abnormal placentae of somatic cell nuclear transfer clone pregnancies in cattle, sheep, and mice. *Veterinary Pathology* **45** 865–880. (<https://doi.org/10.1354/vp.45-6-865>)
- Pozor MA, Sheppard B, Hinrichs K, Kelleman AA, Macpherson ML, Runcan E, Choi YH, Diaw M & Mathews PM 2016 Placental abnormalities in equine pregnancies generated by SCNT from one donor horse. *Theriogenology* **86** 1573–1582. (<https://doi.org/10.1016/j.theriogenology.2016.05.017>)
- Reichert B, Längin M, Denner J, Schwinzer R, Cowan PJ & Wolf E 2020 Pathways to clinical cardiac xenotransplantation. *Transplantation* In Press. (<https://doi.org/10.1097/TP.00000000000003588>)
- Sampaio RV, Sangalli JR, De Bem THC, Ambrizi DR, Del Collado M, Bridi A, de Ávila ACFCM, Macabelli CH, de Jesus Oliveira L, da Silveira JC *et al.* 2020 Catalytic inhibition of H3K9me2 writers disturbs epigenetic marks during bovine nuclear reprogramming. *Scientific Reports* **10** 11493. (<https://doi.org/10.1038/s41598-020-67733-9>)
- Sangalli JR, De Bem THC, Perecin F, Chiaratti MR, Oliveira Lde J, de Araújo RR, Valim Pimentel JR, Smith LC & Meirelles FV 2012 Treatment of nuclear-donor cells or cloned zygotes with chromatin-modifying agents increases histone acetylation but does not improve full-term development of cloned cattle. *Cellular Reprogramming* **14** 235–247. (<https://doi.org/10.1089/cell.2011.0079>)
- Sawai K, Fujii T, Hirayama H, Hashizume T & Minamihashi A 2012 Epigenetic status and full-term development of bovine cloned embryos treated with trichostatin A. *Journal of Reproduction and Development* **58** 302–309. (<https://doi.org/10.1262/jrd.2011-020>)
- Shin T, Kraemer D, Pryor J, Liu L, Rugila J, Howe L, Buck S, Murphy K, Lyons L & Westhusin M 2002 A cat cloned by nuclear transplantation. *Nature* **415** 859. (<https://doi.org/10.1038/nature723>)
- Shinagawa T, Takagi T, Tsukamoto D, Tomaru C, Huynh LM, Sivaraman P, Kumarevel T, Inoue K, Nakato R, Katou Y *et al.* 2014 Histone variants enriched in oocytes enhance reprogramming to induced pluripotent stem cells. *Cell Stem Cell* **14** 217–227. (<https://doi.org/10.1016/j.stem.2013.12.015>)
- Simmet K, Wolf E & Zakhartchenko V 2020 Manipulating the epigenome in nuclear transfer cloning: where, when and how. *International Journal of Molecular Sciences* **22** 236. (<https://doi.org/10.3390/ijms22010236>)
- Sims M & First NL 1994 Production of calves by transfer of nuclei from cultured inner cell mass cells. *PNAS* **91** 6143–6147. (<https://doi.org/10.1073/pnas.91.13.6143>)
- Sinclair KD, Corr SA, Gutierrez CG, Fisher PA, Lee JH, Rathbone AJ, Choi I, Campbell KH & Gardner DS 2016 Healthy ageing of cloned sheep. *Nature Communications* **7** 12359. (<https://doi.org/10.1038/ncomms12359>)
- Smith LC, Wilmut I & Hunter RH 1988 Influence of cell cycle stage at nuclear transplantation on the development in vitro of mouse embryos. *Journal of Reproduction and Fertility* **84** 619–624. (<https://doi.org/10.1530/jrf.0.0840619>)
- Tanaka M, Hennebold JD, Macfarlane J & Adashi EY 2001 A mammalian oocyte-specific linker histone gene H1oo: homology with the genes for the oocyte-specific cleavage stage histone (cs-H1) of sea urchin and the B4/H1M histone of the frog. *Development* **128** 655–664.
- Vanhove B, Duvaux O, Rousse J, Royer P-J, Evanno G, Ciron C, Lheriteau E, Vacher L, Gervois N, Oger R *et al.* 2021 High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2. *European Journal of Immunology* In press. (<https://doi.org/10.1002/eji.202049072>)
- Wang X, Qu J, Li J, He H, Liu Z & Huan Y 2020 Epigenetic reprogramming during somatic cell nuclear transfer: recent progress and future directions. *Frontiers in Genetics* **11** 205. (<https://doi.org/10.3389/fgene.2020.00205>)
- Weier JF, Weier HU, Jung CJ, Gormley M, Zhou Y, Chu LW, Genbacev O, Wright AA & Fisher SJ 2005 Human cytotrophoblasts acquire aneuploidies as they differentiate to an invasive phenotype. *Developmental Biology* **279** 420–432. (<https://doi.org/10.1016/j.ydbio.2004.12.035>)
- Wen D, Banaszynski LA, Liu Y, Geng F, Noh KM, Xiang J, Elemento O, Rosenwaks Z, Allis CD & Rafii S 2014a Histone variant H3.3 is an essential maternal factor for oocyte reprogramming. *PNAS* **111** 7325–7330. (<https://doi.org/10.1073/pnas.1406389111>)
- Wen D, Banaszynski LA, Rosenwaks Z, Allis CD & Rafii S 2014b H3.3 replacement facilitates epigenetic reprogramming of donor nuclei in somatic cell nuclear transfer embryos. *Nucleus* **5** 369–375. (<https://doi.org/10.4161/nucl.36231>)
- Whitelaw CBA, Sheets TP, Lillico SG & Telugu BP 2016 Engineering large animal models of human disease. *Journal of Pathology* **238** 247–256. (<https://doi.org/10.1002/path.4648>)
- Willadsen SM 1986 Nuclear transplantation in sheep embryos. *Nature* **320** 63–65. (<https://doi.org/10.1038/320063a0>)
- Wilmut I, Schnieke AE, McWhir J, Kind AJ & Campbell KH 1997 Viable offspring derived from fetal and adult mammalian cells. *Nature* **385** 810–813. (<https://doi.org/10.1038/385810a0>)
- Wittayarat M, Sato Y, Do LTK, Morita Y, Chatdarong K, Techakumphu M, Taniguchi M & Otoi T 2013 Histone deacetylase inhibitor improves the development and acetylation levels of cat-cow interspecies cloned embryos. *Cellular Reprogramming* **15** 301–308. (<https://doi.org/10.1089/cell.2012.0094>)
- Yang H & Wu Z 2018 Genome editing of pigs for agriculture and biomedicine. *Frontiers in Genetics* **9** 360. (<https://doi.org/10.3389/fgene.2018.00360>)
- Yoshida K, Muratani M, Araki H, Miura F, Suzuki T, Dohmae N, Katou Y, Shirahige K, Ito T & Ishii S 2018 Mapping of histone-binding sites in histone replacement-completed spermatozoa. *Nature Communications* **9** 3885. (<https://doi.org/10.1038/s41467-018-06243-9>)
- Zhang K, Rajput SK, Wang S, Folger JK, Knott JG & Smith GW 2016 CHD1 regulates deposition of histone variant H3.3 during bovine early embryonic development. *Biology of Reproduction* **94** 140. (<https://doi.org/10.1095/biolreprod.116.138693>)

Zhang K, Wang H, Rajput SK, Folger JK & Smith GW 2018 Characterization of H3.3 and HIRA expression and function in bovine early embryos. *Molecular Reproduction and Development* **85** 106–116. (<https://doi.org/10.1002/mrd.22939>)

Zhang C, Chen Z, Yin Q, Fu X, Li Y, Stopka T, Skoultchi AI & Zhang Y 2020a The chromatin remodeler Snf2h is essential for oocyte meiotic cell cycle progression. *Genes and Development* **34** 166–178. (<https://doi.org/10.1101/gad.331157.119>)

Zhang K, Wu DY, Zheng H, Wang Y, Sun QR, Liu X, Wang LY, Xiong WJ, Wang Q, Rhodes JDP *et al.* 2020b Analysis of genome architecture during SCNT reveals a role of cohesin in impeding minor ZGA. *Molecular Cell* **79** 234.e9–250.e9. (<https://doi.org/10.1016/j.molcel.2020.06.001>)

Zuccotti M, Piccinelli A, Giorgi Rossi P, Garagna S & Redi CA 1995 Chromatin organization during mouse oocyte growth. *Molecular Reproduction and Development* **41** 479–485. (<https://doi.org/10.1002/mrd.1080410410>)

Received 12 December 2020

First decision 12 January 2021

Revised Manuscript received 11 February 2021

Accepted 5 March 2021